| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02894515 2016-000405-37 Details | 2016-11-11 Interventional | 1 | 0 | (2-(6-fluoro-1H… Bioequivalence | The study was withdrawn based on new efficacy data from another study - | |||
| NCT00369915 Details | 2016-11-10 Interventional | 2 | 17 | Butylscopolammo… Scopolamine Bipolar Disorde… Depression Depressive Diso… Bipolar Depress… Unipolar Depres… | - - | |||
| NCT01774604 Details | 2016-11-04 Interventional | 3 | 449 | Indomethacin Pancreatitis Post-ERCP Acute… | Futility The study was terminated due to indomethacin's lack of efficacy after 449 patients had been enrolled. Thus the study may be underpowered to draw conclusions about the role of indomethacin in preventing post ERCP pancreatitis | |||
| NCT01702714 2012-003376-39 Details | 2016-11-04 Interventional | 1 | 0 | Carboplatin Gemcitabine Paclitaxel Carcinoma, Non-… Lung Neoplasms Neoplasm Metast… Non-Squamous No… | Project Team decision - | |||
| NCT01579864 2011-000370-59 Details | 2016-11-03 Interventional | 4 | 6 | Rocuronium Succinylcholine Anesthesia | recent publication (Ghezel-Ahmadi. Thorac Cardiovasc Surg. 2014 Nov 21) - | |||
| NCT01151943 2010-019662-88 Details | 2016-11-03 Interventional | 4 | 77 | Anesthetics Anesthetics, Lo… Cesarean Sectio… | The study has been halted prematurely beacuse of the occurence of convulsions in one case after
TAP block. - | |||
| NCT01114997 Details | 2016-11-03 Interventional | 4 | 32 | Esmolol Lidocaine Constipation Vomiting Nausea Pain | The early report didn't show any benefit. - | |||
| NCT00819169 Details | 2016-11-03 Interventional | 1/2 | 89 | Conatumumab Colorectal Canc… Locally Advance… Metastatic Canc… Non-Small Cell … Ovarian Cancer Pancreatic Canc… Sarcoma Solid Tumors | Sponsor decision - subjects rolled over to protocol 20101116 - | |||
| NCT01516476 Details | 2016-11-02 Interventional | 2 | 2 | Liraglutide Diabetes Mellit… Diabetes Mellit… Diabetes Mellit… | - - | |||
| NCT01423539 Details | 2016-11-02 Interventional | 2 | 0 | Bendamustine Hy… Navitoclax Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | The NAVIGATE study has been terminated due to non-safety related reasons. - | |||
| NCT01260194 Details | 2016-11-02 Interventional | 4 | 4 | Trastuzumab Stomach Neoplas… Gastric Cancer | - - | |||
| NCT01179113 Details | 2016-11-02 Interventional | 4 | 33 | Esmolol Laminectomy | The preliminary result didn't show any benefit. - | |||
| NCT01051011 Details | 2016-11-02 Interventional | 3 | 370 | Glucagon-Like P… Insulin Glargin… Metformin Diabetes Mellit… Diabetes Mellit… Diabetes Mellit… | high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation
plan to address hypersensitivity reactions - | |||
| NCT00985374 2008-005806-38 Details | 2016-11-02 Interventional | 1 | 11 | Everolimus Neoplasms | - - | |||
| NCT00845910 Details | 2016-11-02 Interventional | 2 | 22 | Bevacizumab Capecitabine Docetaxel Breast Neoplasm… Breast Cancer | To be confirmed - | |||
| NCT00811993 Details | 2016-11-02 Interventional | 1 | 104 | Bevacizumab Capecitabine Carboplatin Cetuximab Docetaxel Erlotinib Hydro… Etoposide Gemcitabine Irinotecan Sorafenib Temozolomide Trastuzumab Neoplasms | - - | |||
| NCT01882075 Details | 2016-10-31 Interventional | 4 | 2 | Hydroxyethyl St… Anesthesia | Dysfonction of the device - | |||
| NCT00427973 Details | 2016-10-31 Interventional | 2 | [1 Refs] | 17 | Cediranib Carcinoma Carcinoma, Hepa… Liver Neoplasms Adult Primary H… Advanced Adult … Localized Unres… Recurrent Adult… | The study was stopped prior to 2nd stage. Despite reaching the prespecified goal for the first stage of the trial, the study was stopped and did not proceed to the second stage after reviewing the development program of cediranib by AstraZeneca for reasons unrelated to this study. | ||
| NCT01701297 2010-022886-92 Details | 2016-10-28 Interventional | 2 | 10 | Trimethoprim, S… Ascites Fibrosis Liver Cirrhosis Peritonitis Decompensated C… | Unable to obtain QP release certification from the manufacturer (VSL3) for shipment of IMP - | |||
| NCT00346749 Details | 2016-10-28 Interventional | 4 | - | Fluticasone Salmeterol Xina… Xhance Lung Diseases Lung Diseases, … Pulmonary Disea… | The study was terminated due to difficulties with finding sites and subjects willing to
participate. - |